Merck & Co., Inc. MRK NYSE

Merck & Co., Inc. (MRK) generated $2.86B in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $1.03B, free cash flow was $1.82B.

Free cash flow margin was 11.1% of revenue. Cash conversion ratio was 0.96x, suggesting some earnings are non-cash.

The company returned $2.02B in dividends and $1.25B in share buybacks to shareholders during the quarter.

Criteria supported by this page:

• HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (94/100, Pass) — $1.82B (11.1% margin) supports a durable competitive advantage
• INCOME (85/100) — Cash conversion ratio was 0.96x suggests some earnings are non-cash items

Overall SharesGrow Score: 83/100 with 7/7 criteria passed.